Newsletter Subject

Eggs do WHAT to senior brains

From

inhresearch.com

Email Address

mail@mb.inhresearch.com

Sent On

Tue, Jul 13, 2021 04:16 PM

Email Preheader Text

 ‌ Plus, The Dirty Little Secret Behind Cancer Drugs You need to read this. to senior brain

 ‌ Plus, The Dirty Little Secret Behind Cancer Drugs You need to read this. [Health Watch] Sponsored Content Eggs do WHAT to senior brains How often do you eat eggs? Did you know [it does THIS]( to senior brains? [Click here]( --------------------------------------------------------------- The Dirty Little Secret Behind Cancer Drugs If you got cancer, how would your doctors decide what treatment to give you? It’s likely they would turn to guidelines from the U.S. National Comprehensive Cancer Network (NCCN). It’s a little-known group of doctors with big clout. They recommend what cancer drugs should be used in which situations. The NCCN frequently recommends that cancer medications be used beyond the situations for which they were approved by the FDA. Big Pharma loves this. It means they sell more drugs. And that means bigger profit. Cancer drugs, after all, do not come cheap. Many cost more than $100,000 a year. But an alarming study at the Oregon Health & Science University found that there’s little or no evidence behind many of the drug recommendations by the NCCN. Even worse, the study points out that many NCCN doctors have financial ties to the drug industry which could influence their decisions. Dr. Vinjay Prasad led the study. He says the new findings “raise concern that the NCCN justifies the coverage of costly, toxic cancer drugs based on weak evidence.” Pushing Unproven Cancer Drugs Dr. Prasad and his team compared FDA approvals of cancer drugs with NCCN recommendations. When the NCCN made recommendations beyond the FDA’s approvals, they evaluated the evidence behind them. The FDA approved 47 new cancer drugs for 69 different uses over the study period. But the NCCN recommended these drugs for 113 uses. And out of their 44 additional recommendations, only six would eventually get FDA approval because they were found to work. Even more concerning is this… Only 10 of these additional recommendations were based on evidence from randomized controlled trials. Just seven were based on evidence from phase III studies that tested the safety of these drugs. Most relied on small, uncontrolled studies or case reports...or didn’t offer any evidence at all. So why does the NCCN push unproven cancer drugs? --------------------------------------------------------------- Recommended Content Fall asleep faster!? Try THIS crazy technique Want to fall asleep faster? Here's a technique... - Touch the roof of your mouth with your tongue... - Then [DO THIS.]( It sounds weird... but it REALLY can work. And it's 100% backed by science. [Try it here.]( [Click here]( --------------------------------------------------------------- The Big Pharma Connection The study points out that 86% of NCCN members have financial ties to the pharmaceutical industry, with 84% of them receiving personal payments. And 47% get research payments. The NCCN endorsement is linked to reimbursement by commercial insurers and social insurance schemes. It’s something Dr. Prasad has studied before. And he found that it isn’t just the NCCN. The FDA also has a tendency to over-approve these drugs. The agency argues that trials proving effectiveness often take many years. Cancer patients need help now. So they say it’s better to roll out a medication quickly and then monitor its effectiveness. If it doesn’t work, the drug can always be pulled from the market. If it does work, lives will be saved. This may sound sensible. But in practice, it’s not working. Only a small percentage of the new FDA-approved cancer drugs end up helping patients live longer. Dr. Prasad looked at 36 cancer drugs that the FDA approved without proof they helped patients live longer. More than four years later, only five had shown evidence of improved survival. That’s a failure rate of 86%. And even after a medication shows it is useless, the FDA is often slow to pull it from the market. So patients keep on taking it, not realizing their drug is a proven failure. This means years of “bonus” profit for Big Pharma. Don’t Be a Cancer Drug Guinea Pig Since you can’t rely on the FDA or the NCCN to tell you which drugs work and which ones don’t, you have to do your own research. Before you try a new cancer drug, ask your oncologist these eight questions: - Has the drug shown survival benefits in clinical trials? Ask for the evidence that it works. How long did patients live versus those taking a placebo or other drugs? - Has the drug been tested in patients like me? Look for human studies that show the medication has been effective in patients with the same type of cancer, similar age, treatment histories, etc. - Are the survival benefits greater than older, less risky drugs? - If the drug is in ongoing trials, can I get preliminary results? Also ask about the results in animal trials. - Is the medication approved in other countries? If so, what is its track record there? - What side effects am I likely to have? Will any of them be permanent? - Are there related drugs in the same class that are effective? - Will the drug be covered by insurance? When you have cancer, the last thing you need is a drug that is being administered not because it is effective—but because it fattens the wallets of Big Pharma cronies. Editor’s Note: Unlike much of the mainstream media, we don’t accept advertising from Big Pharma. That’s why you can count on us for unbiased medical information. Our only motivation is your good health. Subscribe to our newsletter, Independent Healing. Each month it brings you important health news you won’t find anywhere else. Get more information [HERE](. In Good Health, Amanda Angelini Director The Institute for Natural Healing [References Available Here.]( Related Articles: [5 Foods That Prevent Breast Cancer]( [What Every Man Needs to Know About Prostate Cancer]( [Cannabis Shows Cancer-Fighting Potential]( --------------------------------------------------------------- © 2021 OmniVista Health Media, LLC. All Rights Reserved. For more from OmniVista Health Media, LLC, [visit our website](. To end your free subscription, click here: [Unsubscribe]( Health Watch may be republished with its links intact by non-commercial entities. Health Watch may not be republished for commercial purposes without written permission. This information is offered as a general guideline, not one-size-fits-all medical advice. Talk to your doctor before making any changes in your personal health care regimen. To manage your subscription by mail or for any other subscription issues, write us at: Order Processing Center Attn: Customer Service P.O. Box 925 Frederick, MD 21705 USA

Marketing emails from inhresearch.com

View More
Sent On

11/08/2022

Sent On

11/08/2022

Sent On

11/08/2022

Sent On

10/08/2022

Sent On

10/08/2022

Sent On

09/08/2022

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.